EXPERIENCEMain Study CoordinatorJun 2020 ~ Sep 2022 : A Phase III, Randomized, Multi-Center, Double ... Recruitment, umbrella studyFeb 2023 ~ Dec 2023 : A Phase II, Multicenter, Open-label Study to Evaluate ... 2023 ~ Dec 2023 : Randomized, multicenter, open-label, Phase 3 study of mirvetuximab soravtansine in